Inside The ANDA Parking Lot
A firm will take ownership of US ANDAs from manufacturers unwilling to pay program fees or withdraw the approved generic drug application; is it a novel concept allowing future marketing options or simply fee avoidance?
You may also be interested in...
New draft guidances are an attempt to curb abuse of REMS single shared system process to delay generic entry.
US FDA softens its tone on idea and encourages industry to voice its (predominantly negative) opinion publicly.
Problems with self-identification process caused by timing of legislative renewal may have affected figures used by US FDA to calculate FY 2018 GDUFA fees.